IL1B and lung carcinoma: In the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) that reported on the use of IL-1β blockade with canakinumab to reduce the risk of cardiovascular events, a planned secondary analysis demonstrated reduced risk of de novo diagnoses of lung cancer risk (108).